FIBROGEN INC 4

4 · FIBROGEN INC · Filed Jun 13, 2017

Form 4

Period: 2017-06-09

Director

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2017-06-12−12,000→ 0 total
Exercise: $9.78Exp: 2023-04-17→ Common Stock (12,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2017-06-12−3,000→ 0 total
Exercise: $5.95Exp: 2022-06-27→ Common Stock (3,000 underlying)
Exercise/Conversion
Common Stock
2017-06-09$5.95/sh+3,000$17,850→ 63,000 total
Sale
Common Stock
2017-06-09$29.20/sh−15,000$438,000→ 48,000 total
Exercise/Conversion
Common Stock
2017-06-09$3.50/sh+12,000$42,000→ 60,000 total
Exercise/Conversion
Common Stock
2017-06-12$5.95/sh+3,000$17,850→ 51,000 total
Exercise/Conversion
Common Stock
2017-06-12$9.78/sh+12,000$117,300→ 63,000 total
Sale
Common Stock
2017-06-12$28.57/sh−15,000$428,550→ 48,000 total
Exercise/Conversion
Stock Option (Right to Buy)
2017-06-09−3,000→ 3,000 total
Exercise: $5.95Exp: 2022-06-27→ Common Stock (3,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2017-06-09−12,000→ 0 total
Exercise: $3.50Exp: 2021-03-15→ Common Stock (12,000 underlying)

Footnotes (3)

[F1]The shares were sold at prices ranging from $29.20 to $29.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F2]The shares were sold at prices ranging from $28.50 to $28.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F3]Fully vested.

Documents

1 file